Literature DB >> 12941397

Variola virus immune evasion proteins.

Lance R Dunlop1, Katherine A Oehlberg, Jeremy J Reid, Dilek Avci, Ariella M Rosengard.   

Abstract

Variola virus, the causative agent of smallpox, encodes approximately 200 proteins. Over 80 of these proteins are located in the terminal regions of the genome, where proteins associated with host immune evasion are encoded. To date, only two variola proteins have been characterized. Both are located in the terminal regions and demonstrate immunoregulatory functions. One protein, the smallpox inhibitor of complement enzymes (SPICE), is homologous to a vaccinia virus virulence factor, the vaccinia virus complement-control protein (VCP), which has been found experimentally to be expressed early in the course of vaccinia infection. Both SPICE and VCP are similar in structure and function to the family of mammalian complement regulatory proteins, which function to prevent inadvertent injury to adjacent cells and tissues during complement activation. The second variola protein is the variola virus high-affinity secreted chemokine-binding protein type II (CKBP-II, CBP-II, vCCI), which binds CC-chemokine receptors. The vaccinia homologue of CKBP-II is secreted both early and late in infection. CKBP-II proteins are highly conserved among orthopoxviruses, sharing approximately 85% homology, but are absent in eukaryotes. This characteristic sets it apart from other known virulence factors in orthopoxviruses, which share sequence homology with known mammalian immune regulatory gene products. Future studies of additional variola proteins may help illuminate factors associated with its virulence, pathogenesis and strict human tropism. In addition, these studies may also assist in the development of targeted therapies for the treatment of both smallpox and human immune-related diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941397     DOI: 10.1016/s1286-4579(03)00194-1

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  26 in total

1.  Smallpox: an ancient disease enters the modern era of virogenomics.

Authors:  Grant McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-12       Impact factor: 11.205

2.  Immunophysical properties and prediction of activities for vaccinia virus complement control protein and smallpox inhibitor of complement enzymes using molecular dynamics and electrostatics.

Authors:  Li Zhang; Dimitrios Morikis
Journal:  Biophys J       Date:  2006-02-10       Impact factor: 4.033

3.  Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Richard Hauhart; Celia J Fang; Paula Bertram; John P Atkinson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

4.  Inhibition of complement activation on a model biomaterial surface by streptococcal M protein-derived peptides.

Authors:  Anna E Engberg; Kerstin Sandholm; Fredrik Bexborn; Jenny Persson; Bo Nilsson; Gunnar Lindahl; Kristina N Ekdahl
Journal:  Biomaterials       Date:  2009-01-25       Impact factor: 12.479

Review 5.  The evolutionary biology of poxviruses.

Authors:  Austin L Hughes; Stephanie Irausquin; Robert Friedman
Journal:  Infect Genet Evol       Date:  2009-10-13       Impact factor: 3.342

Review 6.  Killing a killer: what next for smallpox?

Authors:  Grant McFadden
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

7.  Dose-dependent lymphocyte apoptosis following respiratory infection with Vaccinia virus.

Authors:  Nicole L Yates; Rama D Yammani; Martha A Alexander-Miller
Journal:  Virus Res       Date:  2008-08-23       Impact factor: 3.303

8.  Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses.

Authors:  Mohamed R Mohamed; Masmudur M Rahman; Jerry S Lanchbury; Donna Shattuck; Chris Neff; Max Dufford; Nick van Buuren; Katharine Fagan; Michele Barry; Scott Smith; Inger Damon; Grant McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

9.  Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination.

Authors:  Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Gene       Date:  2012-08-23       Impact factor: 3.688

10.  The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon.

Authors:  María del Mar Fernández de Marco; Alí Alejo; Paul Hudson; Inger K Damon; Antonio Alcami
Journal:  FASEB J       Date:  2009-12-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.